Eye Drop Production Sterility Problems Bring Reason For US FDA Guidance Into Sharper Focus

Since FDA provided draft guidance on quality considerations for ophthalmic drugs, steady stream has continued of OTC brand recalls due to manufacturers’ failure to ensure sterility in production processes and purity of ingredients and other components.